拓展PSMA-RLT适用范围:评估体能状态差(ECOG 3)的挑战性mCRPC患者的治疗
本研究纳入18例ECOG体能状态3的转移性去势抵抗性前列腺癌(mCRPC)患者,接受[177Lu]Lu-PSMA-617放射性配体治疗,中位治疗周期2个(范围1-10),平均累积给药活度21.5±15.0 GBq(范围2.7-62.6 GBq)。50%患者达到疾病稳定或部分生化缓解,中位无进展生存期1.3个月、总生存期2.8个月,严重不良事件少见。作者认为PSMA-RLT在该亚组可行且总体耐受良好,ECOG 3状态可考虑不作为RLT的绝对排除标准,未来需前瞻性研究进一步探讨。
要点
- 18例ECOG 3的mCRPC患者接受[177Lu]Lu-PSMA-617治疗,50%达到疾病稳定或部分生化缓解。
- 中位无进展生存期1.3个月,中位总生存期2.8个月。
- 严重不良事件3例:1例3级白细胞减少、1例3级血小板减少、1例3/4级全血细胞减少;未观察到更高等级肾毒性或口干,疲乏症状改善。
核心结论
- 作者认为PSMA-RLT对ECOG 3的mCRPC患者是可行且总体耐受良好的治疗,毒性可控。
- 尽管生存结局有限,作者认为ECOG 3状态可考虑不作为RLT的绝对排除标准。
- 作者提出未来前瞻性研究应进一步探讨PSMA-RLT在该挑战性亚组中的作用。
研究设计与样本
- 本分析纳入18例接受PSMA-RLT的ECOG体能状态3的mCRPC患者。
- 中位治疗周期2个(范围1-10),[177Lu]Lu-PSMA-617平均累积给药活度21.5±15.0 GBq(范围2.7-62.6 GBq)。
- 分析结局及不良事件,包括血液学与肾脏毒性、疲乏和口干。
主要发现
- 50%患者达到疾病稳定或部分生化缓解。
- 中位无进展生存期1.3个月,中位总生存期2.8个月。
- 严重不良事件发生于3例患者:1例3级白细胞减少、1例3级血小板减少、1例3/4级全血细胞减少。
- 未观察到更高等级的RLT诱导肾毒性和口干,队列中疲乏症状改善。
临床怎么用
- 作者认为ECOG 3状态可考虑不作为RLT的绝对排除标准。
局限性
- 作者指出未来前瞻性研究应进一步探讨PSMA-RLT在该挑战性亚组中的作用。
- 作者指出尽管生存结局有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Given the increasing inclusion of ECOG 3 patients in oncology practice, data on this subgroup in the context of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) remain limited. This study evaluates the safety and outcome of PSMA-RLT in metastatic castration-resistant prostate cancer (mCRPC) patients with ECOG performance status 3. METHODS: In this analysis, a cohort of 18 mCRPC patients with ECOG performance status 3 who received PSMA-RLT was examined. The median number of treatment cycles was 2 (range: 1-10), with a mean cumulative administered activity of 21.5 ± 15.0 GBq (range: 2.7-62.6 GBq) of [177Lu]Lu-PSMA-617. Outcome and adverse events including hematologic and renal toxicities, fatigue, and xerostomia were analyzed. RESULTS: 50% of patients achieved either stable disease or a partial biochemical response. Median progression-free survival and overall survival were 1.3 months and 2.8 months, respectively. Severe adverse events were uncommon, occurring in three patients: one developed grade 3 leukopenia, another experienced grade 3 thrombocytopenia, and one patient had pancytopenia of grade 3/4. No higher RLT-induced grade of renal toxicity and xerostomia were observed, whilst symptoms of fatigue improved in the cohort. CONCLUSION: This study indicates that PSMA-RLT is a feasible and overall well-tolerated treatment for mCRPC ECOG 3 patients with manageable toxicity profile. Despite limited survival outcomes, ECOG 3 status may be considered not to be a categorical exclusion criterion for RLT. Future prospective studies should further investigate the role of PSMA-RLT in this challenging subgroup.
引用
- Bastian MB, Wörl B, Blickle A, et al. Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3). Eur J Nucl Med Mol Imaging. 2025. PMID: 40418331. doi:10.1007/s00259-025-07346-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。